PPARA and neoplasm: The non-CHD indications of clinically used drugs included dyslipidemias (PPARA), type 2 diabetes (PPARG and NDUFA13), autoimmune diseases (TNF), neoplasms (RAF1 and PSMA5), circulatory disorders (ABCA1, PLG, ITGB3, and F2), and alcohol-dependency (ALDH2) (Table 1).